Latest CTLA-4 Stories
ImaginAb Expands Portfolio for Immunotherapeutic Drug Development LOS ANGELES, June 3, 2014 /PRNewswire/ -- ImaginAb, Inc.
NKTR-214 combined with anti-PD-1 or anti-CTLA-4 provides significant tumor growth inhibition in both EMT6 breast and CT26 colon tumor models SAN FRANCISCO, June 1, 2014 /PRNewswire/
Cancer cells spread and grow by avoiding detection and destruction by the immune system.
Some of the newest therapies in the war on cancer remove the brakes cancer puts on the immune system.
The first new skin cancer treatment since the 1970s has now gone on sale in Britain.
CAMBRIDGE, Mass., April 5, 2011 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by normalizing the immune response, today presented results from preclinical studies with 2F8, a murine analog of TRX518, a first-in-class immunomodulatory agent currently in a Phase 1 clinical study for the treatment of cancer.
The U.S. Food and Drug Administration today approved the use of ipilimumab for the treatment of previously treated metastatic melanoma.
Two-year results from phase III clinical trials show the experimental immunosuppressive drug belatacept can better preserve kidney function in kidney transplant recipients while preventing graft rejection when compared with the standard immunosuppressive drug cyclosporine.
Transplant patients rely on drugs to prevent graft rejection, but at the cost of serious side effects. The class of immunosuppressive drugs known as calcineurin inhibitors
- Inward knowledge; understanding; conscience.